Pfizer has named Cecile Guegan its first female chief financial officer after an interim tenure that began in August 2026. Her appointment comes as women account for 20% of new CFO selections globally, down from 24% a year earlier. Public filings and hiring data detail the timing, responsibilities and financial terms behind the decision.

Key Takeaways

• Pfizer appointed Cecile Guegan chief financial officer and executive vice president, effective November 1, 2026
• Guegan previously served as interim CFO beginning August 16, following the departure of Dave Denton
• Women accounted for 20% of global CFO appointments during the first nine months of 2026, down from 24% during the same period in 2025
• Women’s share of CFO appointments increased in the Americas despite declining globally
• Pfizer disclosed an annual base salary of $1.3 million and an annual target cash incentive opportunity of $1.3 million for Guegan

Pfizer’s first female CFO, Cecile Guegan, took the permanent finance role on November 1, 2026, after serving as interim chief financial officer since August. The New York-based company confirmed her appointment on November 3 alongside quarterly earnings.

Her promotion comes as women’s share of global CFO appointments declined during the first nine months of 2026. Regional trends differ, however, a distinction that matters when assessing an appointment at a U.S.-based company.

Pfizer’s First Female CFO Moves From Interim to Permanent Role

Pfizer’s board unanimously appointed Guegan chief financial officer and executive vice president, effective November 1, according to its announcement and filing with the Securities and Exchange Commission. She had served as interim chief financial officer since August 16, after Dave Denton departed the previous day.

Denton’s exit was announced in June, when Pfizer said it would conduct an internal and external search. Less than three months after Guegan assumed interim responsibilities, the company confirmed her as his permanent successor.

Guegan has more than 25 years of pharmaceutical finance experience. She joined Pfizer through its acquisition of Wyeth in 2009. Before that transaction, she held finance leadership responsibilities supporting Wyeth businesses in Asia Pacific, Europe, the Middle East, Africa and Canada.

At Pfizer, she has worked across oncology, research and development, and the Global Biopharmaceuticals business. She held a vice president role in research and development finance from 2020 to 2022 before becoming senior vice president of finance for Global Biopharmaceuticals, a position she occupied until her interim appointment.

In that senior role, Pfizer says, Guegan oversaw financial operations and reporting across therapeutic areas and regions. She also worked with commercial leaders on business plans and forecasts.

She holds a master’s degree in management from the Graduate School of Management of Brest, France, and a French accounting qualification. Her prior work also included corporate integration planning, according to the company.

Another female executive appointment in healthcare came in August, when Rupa Bahri was named chief executive of Foundation Consumer Healthcare.

Women’s Share of Global CFO Appointments Fell to 20%

Russell Reynolds Associates’ Global CFO Turnover Index recorded women in 20% of new CFO appointments worldwide from January through September 2026, down from 24% during the comparable period in 2025. The latest proportion was below the index’s eight-year average of 22% and was its lowest since 2019.

The global decline was not consistent across regions. Women’s share of appointments rose to 21% from 18% in the Americas, remained about 26% in Europe, the Middle East and Africa, and fell to 12% from 28% in Asia Pacific. Those differences matter when assessing an appointment by a U.S.-based company.

Russell Reynolds also reported that fewer companies were promoting CFOs from within. Pfizer had announced a search covering internal and external candidates before selecting Guegan, a long-serving company executive.

The index counted 267 CFO appointments at the major publicly traded companies it tracks during the first three quarters of 2026. That was its highest appointment rate for the period in eight years.

Of the new appointees, 52 were women, while 22 women departed CFO positions. Those figures indicate a net increase in female CFO representation across the index during those months, despite women’s smaller share of appointments.

The 20% figure measures new appointments, not the share of existing CFO positions held by women. Fortune reported that women accounted for 24% of CFO appointments in healthcare, a sector-specific figure that does not describe the full population of sitting finance chiefs.

A separate International Labour Organization report estimated that women in management roles held 30.5% of managerial positions worldwide in 2025. Its broader management measure covers a different population from Russell Reynolds Associates’ index of CFO appointments, so the percentages are not directly comparable.

Guegan’s promotion represents one appointment, while the index covers hiring across selected publicly traded companies. The data does not establish why Pfizer chose her.

Pfizer Discloses Guegan’s Responsibilities and $1.3 Million Salary

Guegan now oversees Pfizer’s corporate finance functions, including treasury, tax, audit, insurance, financial reporting, business finance and operational planning. The company also lists corporate controllership and finance analytics among her responsibilities.

Those duties expand on the financial oversight she provided as interim CFO and on her previous work within Pfizer’s biopharmaceutical business. They cover both the company’s reporting obligations and routine financial planning.

Guegan described her focus as “executing a disciplined approach to capital allocation” in Pfizer’s announcement. The company cited her prior planning and reporting experience in outlining her qualifications for the position.

Pfizer also reported third-quarter 2026 revenue of approximately $16.6 billion, relatively flat from a year earlier on an operational basis. Revenue excluding COVID-19 products Comirnaty and Paxlovid increased 7% operationally. Adjusted diluted earnings per share for the quarter were $0.87, unchanged from the same quarter in 2025.

Reported net income was about $3.24 billion, down 8% from $3.54 billion a year earlier, while reported diluted earnings per share declined to $0.56 from $0.62. Pfizer distinguished these reported results from its adjusted figures.

Alongside the results, Pfizer lifted its full-year revenue guidance to $62 billion to $64 billion, compared with the previous range of $60.5 billion to $62.5 billion. It also raised and narrowed its adjusted diluted earnings-per-share forecast to $2.95 to $3.05. These remain company projections, not completed-year results.

The figures describe company performance during the leadership transition, without establishing that Guegan’s interim appointment caused the quarterly results.

The November 3 SEC filing disclosed an annual base salary of $1.3 million and an annual target cash incentive opportunity of $1.3 million, equal to 100% of base pay. The incentive is a target opportunity, not a guaranteed payment. The filing did not establish that the full amount would be paid.

Frequently Asked Questions

Who is Pfizer’s first female CFO?

Cecile Guegan is Pfizer’s first female CFO, appointed permanently effective November 1, 2026. She has more than 25 years of experience in pharmaceutical finance and has held senior financial leadership positions at Pfizer since joining through its acquisition of Wyeth in 2009.

When was Cecile Guegan appointed CFO of Pfizer?

Pfizer announced Guegan’s permanent appointment on November 3, 2026, with an effective date of November 1. She had served as interim chief financial officer since August 16, 2026.

How did women’s share of CFO appointments change in 2026?

According to Russell Reynolds Associates, women accounted for 20% of global CFO appointments during the first nine months of 2026, compared with 24% during the same period in 2025. The share increased in the Americas but declined in Asia Pacific.

What compensation did Pfizer disclose for Cecile Guegan?

Pfizer disclosed an annual base salary of $1.3 million and an annual target cash incentive opportunity of $1.3 million. The target incentive is not a guaranteed payment, and actual compensation may differ from the stated target.